Bill Sibold gets promotion at Sanofi

French pharma major Sanofi (Euronext: SAN) has promoted Bill Sibold to the post of executive vice president Sanofi Genzyme, effective July 1, 2017. In this role, Mr Sibold will be a member of the executive committee.

He succeeds David Meeker, who will leave the company at the end of June after a distinguished 23-year career with Genzyme and Sanofi.

Mr Sibold currently serves as head of Sanofi Genzyme's global multiple sclerosis, oncology and immunology organization, a position he has held since January 2016 and where he has led preparation for the global launches of dupilumab and sarilumab. He joined Sanofi in late 2011 as head of the MS franchise where he oversaw the successful launches of Aubagio (teriflunomide) and Lemtrada (alemtuzumab). As head of Sanofi Genzyme, Mr Sibold will now lead the company's efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology.